Inozyme Pharma to Present at Upcoming Investor Conferences
11. November 2024 08:30 ET
|
Inozyme Pharma Inc.
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare...
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights
05. November 2024 08:30 ET
|
Inozyme Pharma Inc.
- Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 – - Topline data from ENERGY 3, a pivotal trial of INZ-701 in pediatric...
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701
24. Oktober 2024 13:15 ET
|
Inozyme Pharma Inc.
- INZ-701 was well-tolerated and significantly increased plasma pyrophosphate (PPi) levels in patients with end-stage kidney disease (ESKD) undergoing hemodialysis; low PPi levels are associated with...
Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024
17. Oktober 2024 08:30 ET
|
Inozyme Pharma Inc.
BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare...
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors
07. Oktober 2024 08:30 ET
|
Inozyme Pharma Inc.
BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare...
Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting
26. September 2024 08:00 ET
|
Inozyme Pharma Inc.
- Data underscore the urgent need for therapies that address the cardiovascular and musculoskeletal complications and long-term systemic effects of ENPP1 and ABCC6 Deficiencies in children - -...
Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference
29. August 2024 08:30 ET
|
Inozyme Pharma Inc.
BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare...
Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights
06. August 2024 08:30 ET
|
Inozyme Pharma Inc.
Inozyme reported financial results for the second quarter ended June 30, 2024, and provided business highlights.
Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function
25. Juli 2024 08:30 ET
|
Inozyme Pharma Inc.
- Treatment with INZ-701 shown to prevent intimal proliferation in both ENPP1-deficient and wild-type mice, supporting its potential therapeutic application beyond traditional ERT - BOSTON, July 25,...
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
02. Juli 2024 08:30 ET
|
Inozyme Pharma Inc.
BOSTON, July 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for...